Serina Therapeutics (SER) grants CEO 10,100 common shares
Rhea-AI Filing Summary
Serina Therapeutics, Inc. reported that Chief Executive Officer Steven A. Ledger acquired 10,100 shares of common stock as a grant/award on May 26, 2026. The award is recorded at $1.93 per share, and his directly held common stock after this transaction totals 10,100 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,100 shares
Net Buy
1 txn
Insider
LEDGER STEVEN A
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 10,100 | $1.93 | $19K |
Holdings After Transaction:
Common Stock — 10,100 shares (Direct)
Footnotes (1)
- F1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.
Key Figures
Shares granted: 10,100 shares
Grant price: $1.93 per share
Direct holdings after grant: 10,100 shares
3 metrics
Shares granted
10,100 shares
Non-derivative common stock grant on May 26, 2026
Grant price
$1.93 per share
Reported value for the 10,100-share award
Direct holdings after grant
10,100 shares
Total common stock directly held by CEO after transaction
Key Terms
Form 4, grant/award acquisition, non-derivative, weighted average purchase price
4 terms
Form 4 regulatory
"Serina Therapeutics disclosed this insider transaction in a Form 4 filing."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
grant/award acquisition financial
"The filing describes the action as a grant/award acquisition of common stock."
non-derivative financial
"The 10,100-share transaction is reported as a non-derivative common stock holding."
weighted average purchase price financial
"A footnote references a weighted average purchase price across multiple transactions."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Serina Therapeutics (SER) disclose in this Form 4 filing?
Serina Therapeutics disclosed that CEO Steven A. Ledger received a grant of 10,100 shares of common stock. The non-derivative award was recorded at $1.93 per share, bringing his directly held common stock position to 10,100 shares following the transaction.
Is the Serina Therapeutics CEO transaction an open-market buy or a grant?
The transaction is reported as a grant or award acquisition, not an open-market purchase. The Form 4 uses transaction code “A” and describes the action as a grant/award acquisition of 10,100 non-derivative common shares at a reported value of $1.93 per share.